Press Release Details

Agios Pharmaceuticals to Present New Research at the 12th International Congress of Inborn Errors of Metabolism

Sep 03, 2013
PDF Version

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 3, 2013-- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), today announced that preclinical data from the company’s research in dysregulated metabolism will be featured in oral and poster presentations at the 12thInternational Congress of Inborn Errors of Metabolism (ICIEM), taking place September 3-6, 2013 in Barcelona, Spain.

“We are eager to participate in this important conference, and look forward to the opportunity to collaborate with world leaders in the scientific understanding of inborn errors of metabolism,” said Scott Biller, Ph.D., chief scientific officer at Agios. “The scientific presentations focus on Type II D-2 hydroxyglutaric aciduria, a rare and severe neurometabolic disorder. Our findings suggest that IDH2 inhibitors could play a role in mitigating this devastating disease, and highlight the potential of a new avenue to develop novel therapeutic options for patients with rare metabolic genetic diseases.”

The schedule for Agios’ presentations is as follows:

Date & Time:

 

Wednesday, September 4, 2013 at 1:00 – 2:00p.m. CEST

Session Type:

Poster presentation

Presentation Title:

P-251 Small molecule inhibition of IDH2(R140Q) in lymphoblasts

 

of D-2-hydroxyglutaric aciduria type II patients

Presenter:

Kimberly S. Straley, scientist, biology

Location:

Poster Hall, Level-1

Date & Time:

  Thursday, September 5, 2013 at 12:15p.m. CEST

Session Title:

Workshop 6 – The Potential of Model Systems to Understand Inborn
Errors of Metabolism

Session Type:

Oral presentation

Presentation Title:

W-020. Mice with IDH2 (p.R140Q) knock-in mutation modeling human
type II D-2-hydroxyglutaric aciduria

Presenter:

Shengfang Jin, Ph.D., senior director, biology

Location:

Room F

About Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals is focused on discovering and developing novel drugs to treat cancer and rare metabolic genetic diseases (known as inborn errors of metabolism or IEMs) through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class lead product candidates in cancer metabolism and IEMs advancing toward the clinic. All Agios programs focus on genetically identified patient populations leveraging our knowledge of metabolism, biology and genomics. For more information, please visit our website at www.agios.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “believe,” “expect” “could,” “should,” “will,” “may” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to important risks and uncertainties that may cause actual events or results to differ materially from Agios’ current expectations and beliefs, including the risks described under the caption “Risk Factors” in Agios’ Registration Statement on Form S-1 which was declared effective by the Securities and Exchange Commission (SEC) on July 23, 2013, and other filings that Agios may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Source: Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.
Media Contact:
Dan Budwick, 973-271-6085
dan@purecommunicationsinc.com
or
Investor Contact:
Glenn Goddard
investors@agios.com